- Optimi (OPTI) is partnering with psilocybin patient advocate Thomas Hartle to produce a Canadian-grown and harvested natural therapeutic psilocybin product for patient use
- Hartle’s charitable vision addresses equality and the lack of access to psilocybin-assisted therapy for vulnerable and underserved populations
- The new product will be unveiled at a virtual press conference on Wednesday, August 10, 2022 at 1:00 pm ET
- Optimi Health Corp. (OPTI) is down 2.70 per cent, trading at C$0.36 per share at 9:50 am ET
Optimi (OPTI) is partnering with psilocybin patient advocate Thomas Hartle to produce a Canadian-grown and harvested natural therapeutic psilocybin product for patient use.
Hartle’s charitable vision addresses equality and the lack of access to psilocybin-assisted therapy for vulnerable and underserved populations. Optimi has called this a critical component of the new partnership agreement.
Optimi Health CEO Bill Ciprick said that a problem needs to be solved – vulnerable and underserved adults are often excluded from the benefits of psilocybin therapy based on social, economic, gender, and racial factors beyond their control.
“Pain doesn’t discriminate, so hopefully our announcement with Thomas is a step in the right direction in addressing this urgent need.”
Thomas Hartle added that it wasn’t until he started receiving his psilocybin-assisted therapy treatments two years ago, he wasn’t sure if he could handle the daily stress of knowing that he was dying.
“Having a therapeutic psilocybin product made in my honour, which I had never considered as a possibility, gives me pause to reflect on how many have lost their battles before ever experiencing the amazing benefits of psilocybin therapy. I am excited to be partnering with Optimi to provide that opportunity to the people who need it most, with the hope that they will receive the same life restoring gift that I have experienced.”
The company intends to donate the proceeds from product sales directly to his charity to facilitate patient access to psilocybin-assisted therapy.
The new product will be unveiled at a virtual press conference on Wednesday, August 10, 2022 at 1:00 pm ET where Optimi executives and Mr. Hartle will discuss details of the partnership.
Optimi Health focuses on producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms for the health and wellness markets.
Optimi Health Corp. (OPTI) is down 2.70 per cent, trading at C$0.36 per share at 9:50 am ET.
